@article{bender2004_44667,
  title = {Safety and efficacy of combined clozapine–lithium pharmacotherapy},
  author = {Bender, Stefan and Linka, Thomas and Wolstein, Jörg and Gehendges, Susanne and Paulus, Hermann-Josef and Schall, Ulrich and Gastpar, Markus},
  year = {2004},
  journal = {The international journal of neuropsychopharmacology : official scientific journal of the Collegium Internationale Neuro-Psychopharmacologicum (CINP)},
  volume = {7},
  number = {1},
  pages = {59-63},
  publisher = {Univ. Press},
  address = {Cambridge},
  issn = {1461-1457},
  doi = {10.1017/S1461145703003870},
  url = {https://fis.uni-bamberg.de/handle/uniba/44667},
  language = {eng},
  abstract = {Several case reports described neurotoxic side-effects in the course of a combined clozapine-lithium treatment. Here we report on the safety and efficacy of this combination in a sample of 44 hospital patients. Medical records were retrospectively audited and a subsample of 23 patients was re-assessed. Mean total duration of combined treatment was 23.5 months. The combination (indications: prophylaxis; treatment of affective symptoms or aggression/excitement; augmentation of neuroleptic efficacy) was rated effective in 84\% and adverse events were reported in 64\% of the patients. Notably, most of the adverse events were benign and transient. However, 8 patients (18\%) developed transient neurological adverse events that were genuinely novel in only 3 patients (7\%) and coincided with high dosage of medication or high plasma levels or serotonergic (antidepressant) co-medication. Our data suggest that combined clozapine-lithium treatment may appear to be safe and effective when administered within a moderate therapeutic dose range and without serotonergic co-medication or other substances interfering with clozapine metabolism.}
}
